Rebus Holdings, Inc.

Equities

RBSH

US75619J1034

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 07:35:38 25/06/2024 pm IST			5-day change	1st Jan Change
0.0001 ^USD	0.00%		0.00%	-98.04%

2023	Rebus Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
2023	Rebus Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

Genspera, Inc. Announces Resignation of Nancy Jean Barnabei as Vice President Finance, Treasurer and Principal Accounting Officer

May 08, 2013 at 03:57 pm IST

Genspera, Inc. received the resignation of Nancy Jean Barnabei as Vice President Finance, Treasurer and Principal Accounting Officer. Ms. Barnabei's final date of employment has yet to be determined but is anticipated to be no later than June 30, 2013.

Latest news about Rebus Holdings, Inc.

Rebus Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	22/23/22	CI
Rebus Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
Rebus Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	01/23/01	CI
Rebus Holdings, Inc. Auditor Raises 'Going Concern' Doubt	31/23/31	CI
Rebus Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22/22/22	CI
Rebus Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/22/12	CI
Rebus Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	14/22/14	CI
Rebus Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	01/22/01	CI
Rebus Holdings, Inc. Auditor Raises 'Going Concern' Doubt	31/22/31	CI
Rebus Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	13/21/13	CI
Inspyr Therapeutics Announces New Holding Company Structure	12/21/12	CI
Inspyr Therapeutics, Inc. Announces Earnings Results for the Second Quarter Ended June 30, 2021	17/21/17	CI
Inspyr Therapeutics, Inc. Announces Resignation of Michael Cain as Chief Executive Officer	21/21/21	CI
Inspyr Therapeutics, Inc. announced that it has received $0.6 million in funding	18/21/18	CI
Inspyr Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	18/21/18	CI
Inspyr Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	01/21/01	CI
Inspyr Therapeutics, Inc. announced that it has received $0.5 million in funding	12/21/12	CI
Inspyr Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	21/20/21	CI
Inspyr Therapeutics, Inc. announced that it has received $0.5 million in funding	23/20/23	CI
Inspyr Therapeutics, Inc. Enters into Termination of License Agreement with Ridgeway Therapeutics, Inc	09/20/09	CI
Inspyr Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	15/20/15	CI
Inspyr Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	07/20/07	CI
Inspyr Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	15/20/15	CI
Inspyr Therapeutics, Inc. announced that it has received $0.25 million in funding	06/20/06	CI
Inspyr Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	21/19/21	CI

Chart Rebus Holdings, Inc.

Duration

Period

More charts

Company Profile

Rebus Holdings, Inc. is a pharmaceutical company. The Company is focused on the research and development of targeted precision therapeutics for the treatment of cancer. The Company utilizes its proprietary delivery technology to enhance immuno-modulation for developing therapeutic outcomes. Its immune-oncology lead asset, RT-AR001, is an adenosine A2A receptor antagonist, is differentiated by its intratumoral delivery of nano- or microparticle formulations that allow for better tumor infiltration. Its patented portfolio of adenosine receptor antagonists provides treatment based on the specific adenosine targets found in each type of cancer. The adenosine receptor modulators include A2A, A2B and dual A2A/A2B antagonists, that have broad development applicability, including indications within immuno-oncology. It is also engaged in the manufacturing of platform delivery systems for nano- or microparticle formulations that are used in toxicology studies.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
REBUS HOLDINGS, INC.	-98.04%	3.21K
VERTEX PHARMACEUTICALS INCORPORATED	+16.45%	123B
REGENERON PHARMACEUTICALS, INC.	+21.96%	115B
ARGENX SE	+23.73%	25.85B
BIONTECH SE	-20.05%	20.9B
BEIGENE, LTD.	-16.28%	16.77B
GENMAB A/S	-16.52%	16.52B
WUXI APPTEC CO., LTD.	-44.35%	15.56B
SAREPTA THERAPEUTICS, INC.	+63.91%	15.49B
NEUROCRINE BIOSCIENCES, INC.	+2.52%	13.45B

Bio Therapeutic Drugs